IntelGenx, PediPharm Ltd. deal

IntelGenx received exclusive, worldwide rights from PediPharm to INT0010 to manage symptoms of multiple sclerosis-induced neuropathic pain and chemotherapy-induced nausea. PediPharm is eligible for a signing fee, a milestone payment and royalties upon IntelGenx securing a commercialization partner. INT0010 is a buckle tablet formulation of dronabinol (delta-9-tetrahydrocannabinol, THC), with a Phase II trial slated for next half for neuropathic pain. Further financial terms were not disclosed. ...